NCT05019716View on ClinicalTrials.gov

Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Advanced NUT CarcinomaMetastatic NUT CarcinomaUnresectable NUT Carcinoma
Interventions
DRUG

BET Bromodomain Inhibitor ZEN-3694

Given PO

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood and urine sample collection

PROCEDURE

Chest Radiography

Undergo chest x-ray

DRUG

Cisplatin

Given IV

PROCEDURE

Computed Tomography

Undergo CT or PET-CT

DRUG

Etoposide

Given IV

PROCEDURE

FDG-Positron Emission Tomography

Undergo FDG-PET

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET-CT

Trial Locations (5)

15232

RECRUITING

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

77030

RECRUITING

M D Anderson Cancer Center, Houston

90033

RECRUITING

Los Angeles General Medical Center, Los Angeles

RECRUITING

USC / Norris Comprehensive Cancer Center, Los Angeles

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH